Indefinite Delivery Contract 75D30120D07113
Award Date
12/17/19
Last Date to Order
2/28/21
Federal Agency
CDC Pittsburgh
Awardee
Astrazeneca Pharmaceuticals LP
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
This indefinite delivery contract was awarded by the Centers for Disease Control and Prevention (CDC), a civilian agency within the Department of Health and Human Services (HHS), to AstraZeneca Pharmaceuticals LP, a foreign-owned, for-profit pharmaceutical manufacturer. The contract, valued at $377,600,000.00, is for the procurement of influenza vaccines to support adult and pediatric immunization programs. AstraZeneca, a leading global biopharmaceutical company, has a history of providing...
The Centers for Disease Control and Prevention (CDC) has awarded Astrazeneca Pharmaceuticals LP, a foreign-owned pharmaceutical manufacturer, an Indefinite Delivery Contract worth up to $75.52 million to provide pediatric influenza vaccines for the 2022-2023 season. The contract has a period of performance from January 5, 2022 through February 28, 2023. Under this contract, Astrazeneca will deliver between 100 doses to 50 million doses of influenza vaccine for children ages 0 through 18 to CDC...
This indefinite delivery contract was awarded by the Centers for Disease Control and Prevention (CDC) to AstraZeneca Pharmaceuticals LP, a foreign-owned pharmaceutical manufacturer, on December 31, 2024. The contract has a ceiling value of $51,900,000 and a period of performance through February 28, 2026. The primary purpose of this IDV is to procure pediatric influenza vaccines for the 2025-2026 season. AstraZeneca, as the prime contractor, will provide these vaccines to the CDC and potentially...
This Indefinite Delivery Contract (IDC) was awarded by the U.S. Centers for Disease Control and Prevention (CDC), a civilian federal agency, to AstraZeneca Pharmaceuticals LP, a foreign-owned, for-profit pharmaceutical manufacturer. The contract ceiling value is $15,136,570.80 with a period of performance through February 28, 2025. The purpose of this IDC is to procure pediatric influenza vaccines for the 2024-2025 timeframe. AstraZeneca, a leading global biopharmaceutical company, has a history...
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to AstraZeneca Pharmaceuticals LP, a foreign-owned, for-profit pharmaceutical manufacturer. The IDC, valued at $24,672,000.00, is for the procurement of adult influenza vaccines for the 2020-2021 timeframe. As a multiple award IDC, this contract vehicle allows the CDC to issue task orders to AstraZeneca and other qualified vendors to fulfill adult influenza vaccine requirements....
This Indefinite Delivery Contract (IDC) is a multiple-award vehicle awarded by the Centers for Disease Control and Prevention (CDC), a civilian federal agency under the Department of Health and Human Services, to AstraZeneca Pharmaceuticals LP, a foreign-owned, for-profit pharmaceutical manufacturer. The contract has a ceiling value of $8,820,000.00 and a period of performance through February 28, 2025, for the procurement of adult influenza vaccines during the 2024-2025 flu season....
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to AstraZeneca Pharmaceuticals LP, a large foreign-owned pharmaceutical manufacturer, to provide adult influenza vaccines for the 2025-2026 season. The $9,050,000 multiple-award IDC has a period of performance through February 2026. As a large business, AstraZeneca did not receive a small business set-aside for this contract. AstraZeneca has a broad portfolio of federal contracts and...
This indefinite delivery contract was awarded by the Department of Health and Human Services Centers for Disease Control and Prevention Pittsburgh to provide pediatric flu vaccines for 2023-2024. Astrazeneca Pharmaceuticals LP is the prime contractor for this multiple-award contract with a potential value of $58.53M. The contract aims to procure pediatric flu vaccines through a series of task orders against an established price list. As the lead federal agency for public health emergency...
The Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense awarded an Other Transaction Agreement (OTA) to AstraZeneca Pharmaceuticals LP, a foreign-owned for-profit pharmaceutical manufacturer, on October 28, 2020. The award has a potential value of $857,061,969.19 and is focused on the development of AstraZeneca's COVID-19 vaccine. AstraZeneca has a history of providing a range of pharmaceutical products and medical countermeasures to federal agencies,...
This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency's Medical Supply Chain program to Astrazeneca Pharmaceuticals LP, a foreign-owned, for-profit pharmaceutical manufacturer. The $5,360,046.82 ceiling value contract has a period of performance from November 16, 2016 to November 15, 2026 and includes no set-aside designations. Under this IDC, Astrazeneca has been awarded multiple Firm Fixed Price delivery orders to provide a variety of "Other Medical"...